Treatment-related biomarkers in pulmonary hypertension patients on oral therapies

Respiratory Research

Table 3 Relationship between 6MWD and same-visit biomarkers in a larger cohort of subjects with pulmonary vascular disease

Biomarker^a	Estimate	Standard error	p-value
ET-1 (N = 98)	− 33.51	13.82	0.017
NTproBNP (N = 99)
Log(NTproBNP + 1) ≤ 5.5, per 1 unit increase	− 7.02	5.83	0.23
Log(NTproBNP + 1) > 5.5, per 1 unit increase^b
PAH on treatment with ERA	− 4.88	16.04	0.76
PAH on treatment with PDE5i	− 41.40	42.51	0.33
PAH on treatment with ERA + PDE5i	− 42.26	10.84	0.0002
PAH with concomitant left heart disease	− 43.89	18.84	0.021
PAH with concomitant lung disease	1.33	18.56	0.94
CTEPH	− 77.10	18.94	< .0001
RDW (N = 99)	− 179.30	54.84	0.001
cGMP (N = 96)	− 0.001	7.65	0.99
SNO-Hb (N = 92)	− 302.57	2498.01	0.90
cGMP/NTproBNP ratio (N = 94)
Log(cGMP/NTproBNP + 1) ≤ 0.3, per 1 unit increase	205.01	59.11	0.0008
Log(cGMP/NTproBNP + 1) > 0.3, per 1 unit increase	8.48	18.33	0.64
NO2⁻ (N = 90)	1.85	5.49	0.74
SDMA (N = 97)
Log(SDMA + 1) ≤ 6, per 1 unit increase	37.10	36.53	0.31
Log(SDMA + 1) > 6, per 1 unit increase	− 47.93	17.84	0.008
ADMA by therapy class and comorbidities (N = 98)^c
ADMA, PAH on treatment with ERA	− 0.23	0.086	0.01
ADMA, PAH on treatment with PDE5i	− 0.035	0.11	0.75
ADMA, PAH on treatment with ERA + PDE5i	0.098	0.086	0.26
ADMA, PAH with concomitant left heart disease	0.10	0.10	0.32
ADMA, PAH with concomitant lung disease	− 0.20	0.093	0.031
ADMA, CTEPH	− 0.20	0.16	0.21

^aAll biomarkers are transformed as log(biomarker + 1) with the exception of ADMA. All models were adjusted for age
^bInteraction p = 0.028
^cInteraction p = 0.032

ISSN: 1465-993X